SCHEDULE: Vanguard Group Discloses 3.34% Stake in Applied Therapeutics

The Vanguard Group has filed an amended Schedule 13G, revealing a 3.34% beneficial ownership stake in Applied Therapeutics Inc. as of June 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 4,734,013 shares of Applied Therapeutics Inc. common stock.
• This represents 3.34% of the company's common stock outstanding.
• Vanguard holds sole dispositive power over 4,703,284 shares and shared dispositive power over 30,729 shares.
• Vanguard holds no voting power, either sole or shared.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive ownership stake by a major institutional investor, The Vanguard Group, which can be viewed as a positive signal of inclusion in their investment portfolios. However, it does not provide any direct insights into the company's operational performance or future prospects.

Positives

• A major institutional investor like The Vanguard Group holds a significant stake, indicating their confidence or inclusion of the stock in their index funds.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, long-term investment approach.

Negatives

• The filing itself does not present any negative aspects related to the company's performance or outlook, as it is purely a disclosure of ownership.

Risks

• The filing does not detail specific risks related to Applied Therapeutics Inc.'s operations or financial health. It only states that Vanguard's acquisition and holding of securities are in the ordinary course of business and not for control purposes, which mitigates the risk of activist investor intervention.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Recommendation

The filing is a routine disclosure of passive ownership by a large institutional investor. It does not provide new information about the company's fundamentals, financial performance, or strategic direction that would warrant a change in investment recommendation. The presence of Vanguard as a holder is generally a neutral to slightly positive signal, suggesting the stock is part of broader market indices or passively managed funds. Investors should base their decisions on the company's core business performance and future prospects, not solely on this ownership disclosure.

Keywords

Applied Therapeutics Inc, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, ATNM, Investment Adviser